RecruitingPhase 1NCT06326021

Optimised CD33 (FL-33) CAR T Therapy for Refractory/Relapsed Acute Myeloid Leukaemia

Studying Acute graft versus host disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Beijing GoBroad Hospital
Intervention
autologous FL-33 CAR T therapy(drug)
Enrollment
27 enrolled
Eligibility
1-70 years · All sexes
Timeline
20242026

Study locations (4)

Collaborators

The General Hospital of Western Theater Command · Zhaxin Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai · Shanghai Liquan Hospital · Ruijin Hospital

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06326021 on ClinicalTrials.gov

Other trials for Acute graft versus host disease

Additional recruiting or active studies for the same condition.

See all trials for Acute graft versus host disease

← Back to all trials